Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine dosing with docetaxel in metastatic breast cancer
NCT00077857Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2003
- Primary completion
- Mar 2010
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of capecitabine in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Time to Progression of Disease or Death at 16 months. Started Jul 2003; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00077857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00077857.